Research Article

Difference between Acyclovir and Ganciclovir in the Treatment of Children with Epstein–Barr Virus- Associated Infectious Mononucleosis

Shouyuan Zhang,1 Yanyan Zhu,2 Yanyan Jin,3 Hong Sun,1 Weiqun Wang,1 and Lu Zhan1

1Department of Pediatrics, Zhejiang Hospital of Integrated Traditional Chinese and Western Medicine, Hangzhou, Zhejiang 310003, China
2Department of Pediatrics, Hangzhou Children’s Hospital, Hangzhou, Zhejiang 310010, China
3Department of Pediatrics, Children’s Hospital Affiliated to Zhejiang University, Hangzhou, Zhejiang 310003, China

Correspondence should be addressed to Lu Zhan; zjiyuan1014@163.com

Received 9 September 2021; Accepted 4 October 2021; Published 20 October 2021

Academic Editor: Songwen Tan

Copyright © 2021 Shouyuan Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. To investigate the efficacy differences between acyclovir and ganciclovir in the treatment of children with Epstein–Barr virus (EBV)- associated infectious mononucleosis (IM).

Methods. A total of 128 children with EBV-IM who were admitted to our hospital from February 2019 to February 2021 were selected and randomly divided into the acyclovir group (n = 64) and the ganciclovir group (n = 64) according to the random number table method. All the children were given symptomatic treatments such as protecting the liver and reducing fever. On this basis, the acyclovir group was given an intravenous drip of acyclovir, while the ganciclovir group was given an intravenous drip of ganciclovir. The treatment was continued for 7 days. After the treatment, the clinical efficacy, disappearance time of symptoms and signs, related blood routine indexes, EBV-DNA negative conversion rate, and the incidence of adverse reactions during the treatment were compared between the two groups.

Results. After treatment, the total effective rate of the ganciclovir group (92.19%) was higher than that of the acyclovir group (73.44%) and the difference was statistically significant (P < 0.05). The disappearance time for the symptoms and signs of angina, fever, lymphadenopathy, hepatomegaly, and splenomegaly in the ganciclovir group was lower than that in the acyclovir group, and the difference was statistically significant (P < 0.05). After treatment, the levels of atypical lymphocyte proportion, lymphocyte proportion, and WBC count in the two groups were lower than those before treatment, the levels in the ganciclovir group were lower than those in the acyclovir group, and the difference was statistically significant (P < 0.05). After treatment, the EBV-DNA negative conversion rate (81.25%) in the ganciclovir group was higher than that in the acyclovir group (60.93%) and the difference was statistically significant (P < 0.05). During treatment, the incidence of adverse reactions in the ganciclovir group was significantly lower than that in the acyclovir group and the difference was statistically significant (P < 0.05). Conclusion. In the treatment of children with EBV-IM, the therapeutic effect of ganciclovir is obviously superior to that of acyclovir. Ganciclovir can quickly eliminate the symptoms of angina, fever, enlarged lymph nodes, and other signs in children, can improve abnormal blood indicators, and has a higher negative conversion rate of EBV and less adverse reactions.

1. Introduction

Infectious mononucleosis (IM) has a high incidence rate in children, which is often caused by the infection by the herpes family virus Epstein–Barr virus (EBV). The main clinical symptoms include angina, fever, hepatosplenomegaly, and so on [1]. If not treated in time, the disease easily develops into a malignant disease related to chronic active EBV infection and causes multisystem damage [2]. Compared with adults, it is more harmful in children. In addition to symptomatic treatment, the use of antiviral drugs for the treatment of EBV-IM has been widely recognized in clinical
2.2. Research Methods

2.2.1. Therapeutic Method. All children were given symptomatic treatments such as liver protection and myocardial nutrition support. On this basis, the acyclovir group was given acyclovir injection (10 mg/kg) combined with 100 ml glucose injection using an intravenous drip twice a day. The ganciclovir group was given ganciclovir injection (10 mg/kg) combined with 100 ml glucose injection using an intravenous drip twice a day. All patients were treated with a slow drip, and each drip lasted more than 1 hour. All children were treated continuously for 7 days, during which the drug dose was adjusted according to the adverse reactions and remission degree of the disease. (In order to avoid the interference of different drug injection methods on the experimental results, acyclovir and ganciclovir were slowly and intravenously injected in the same way in this study.)

2.2.2. Observation Index. The disappearance time of typical IM symptoms of the two groups of children was recorded and compared, including angina, fever, lymphadenopathy, hepatomegaly, and splenomegaly.

Before and after treatment, all children were given routine blood tests. Atypical lymphocyte ratio, lymphocyte ratio, and leukocyte count were compared between the two groups.

Before and after treatment, the fluorescence quantitative polymerase chain reaction (PCR) test was used to detect the EBV-DNA level in the whole blood of children. The number of cycle times (CT value) required for the fluorescence intensity of the sample to reach the threshold value was ≤ 39, representing the positivity of EBV-DNA in children. The negative conversion rates, decline, and no changes (including increases) were compared between the two groups.

The adverse reactions including arrhythmia, abnormal liver function, thrombocytopenia, leukopenia, and gastrointestinal reaction were recorded and compared between the two groups during the treatment. (If the child suffers from new liver dysfunction during treatment or the liver dysfunction aggravates, the liver dysfunction will be considered as an adverse reaction of the therapeutic drugs.)

2.2.3. Efficacy Criteria. Markedly effective criteria are as follows: within 3 days after medication, the temperature returns to normal within 3 days, EBV-DNA becomes negative or decrease, and clinical symptoms such as angina and hepatosplenomegaly significantly improve or disappear. Effective criteria are as follows: within 5 days after medication, the temperature returns to normal, EBV-DNA decreases, and clinical symptoms such as angina and hepatosplenomegaly improve or disappear. Unless otherwise stated above, it shall be deemed as invalid. Total effective rate = (markedly effective cases + effective cases)/total cases × 100%.

2.3. Statistical Methods. SPSS19.0 software was used for processing, measurement data were expressed by mean ± standard deviation (mean ± SD), and pairwise comparison was analyzed by the t-test. The enumeration data were compared among groups using the χ² test. P < 0.05 indicates that the difference was statistically significant.

3. Results

3.1. Comparison of Clinical Effects between Two Groups. After treatment, the total effective rate of the ganciclovir group (92.19%) was higher than that of the acyclovir group (73.44%) and the difference was statistically significant (P < 0.05), as shown in Table 1.
3.2. Comparison of Disappearance Time of Clinical Symptoms and Physical Signs between Two Groups. The disappearance time for the symptoms and signs of angina, fever, lymphadenopathy, hepatomegaly, and splenomegaly in the ganciclovir group was lower than that in the acyclovir group and the difference was statistically significant ($P < 0.05$), as shown in Figure 1.

3.3. Comparison of Related Blood Routine Indexes between Two Groups. After treatment, the levels of atypical lymphocyte proportion, lymphocyte proportion, and WBC count in the two groups were lower than those before treatment, the levels in the ganciclovir group were lower than those in the acyclovir group, and the difference was statistically significant ($P < 0.05$), as shown in Figures 2~4.

3.4. Comparison of EBV-DNA Negative Conversion Rate between Two Groups. After treatment, the EBV-DNA negative conversion rate (81.25%) in the ganciclovir group was higher than that in the acyclovir group (60.93%) and the difference was statistically significant ($P < 0.05$), as shown in Table 2.

3.5. Comparison of the Incidence of Adverse Reactions between Two Groups. During treatment, the incidence of adverse reactions in the ganciclovir group was significantly lower than that in the acyclovir group and the difference was statistically significant ($P < 0.05$), as shown in Table 3.

4. Discussion

Children’s IM is mostly caused by EBV, which is one of the herpes viruses. EBV can cause damages to multiple organs of the whole body and can be transmitted through the respiratory tract [8]. When IM is caused, the clinical manifestations mainly include sore throat, fever, lymph nodes, hepatosplenomegaly, and so on. When the disease is at the beginning stage, the routine blood test is usually unremarkable, so EBV has a high rate of being missed and misdiagnosed. If it is not treated in time, the disease can develop rapidly and even lead to disability or death [9, 10]. At present, there is no specific drug for the treatment of IM and symptomatic treatment is often adopted to enhance the autoimmune function of children, and antiviral drug intervention is combined to significantly improve the treatment effect. Clinically, many drugs are used against EBV, such as acyclovir, ganciclovir, and ribavirin. Ganciclovir is a derivative of acyclovir. They are nucleoside antiviral drugs that have the function of inhibiting the synthesis of EBV-DNA. The anti-EBV effect of them is stronger than other drugs [11, 12]. However, the therapeutic effect and difference between them in the treatment of children with EBV-IM are still uncertain.
The results of this study showed that after treatment, the total effective rate of the ganciclovir group was significantly higher than that of the acyclovir group and the disappearance time of typical clinical symptoms such as angina, fever, and hepatosplenomegaly in the ganciclovir group was significantly lower than that in the acyclovir group. Acyclovir and ganciclovir both showed good effects on the normally high proportion of abnormal lymphocytes, proportion of lymphocytes, and white blood cell count, but ganciclovir showed better effects. Ganciclovir has a broader antiviral spectrum than acyclovir, and the DNA polymerase of the EBV is highly sensitive to both triphosphates of acyclovir and ganciclovir [13, 14]. Ganciclovir is converted into activated triphosphate by thymidine kinase action in infected cells, which competitively inhibits viral DNA polymerase, terminates EBV-DNA prolongation, and inhibits replication of its viral products. Furthermore, ganciclovir is more water soluble than acyclovir, and the drug activity of ganciclovir in Epstein–Barr virus infected cells is 100 times higher than that in non-Epstein–Barr virus infected cells, where its efficacy can last for several days. Acyclovir does not have these characteristics, so ganciclovir has better curative effect [15].

EBV infection can cause hemophagocytic syndrome, myocarditis, lymphoma, meningitis, and many other critical illnesses, and children’s immune system is not yet fully developed, so their condition develops more rapidly [16]. With the increase in the EBV-DNA load, the risk of complications, the degree of organ damage, the severity of the disease, and the mortality rate of children are significantly increased [17]. In children whose symptoms have resolved but in whom EBV is still not positive, there is still a certain risk of recurrent episodes of IM that develop into chronic EB virus infection [18]. The quantitative PCR test can accurately reflect the degree of EBV infection and the number of virus replications in children. EBV-DNA test results showed that after seven days of treatment, the negative conversion rate of EBV-DNA in the ganciclovir group was 81.25%, significantly higher than that of the acyclovir group (60.93%). In addition, only 6 children in the ganciclovir group had the same viral load, while 12 children in the acyclovir group had the same viral load. However, it was possible that because of the small sample size, the comparison between the two groups of unchanged children was not statistically significant. The above results indicated that ganciclovir had a stronger antiviral effect against EB virus than acyclovir. Hence, timely application of ganciclovir to children with IM could effectively prevent a series of other critical illnesses caused by EB virus, such as meningitis, in children.

Although acyclovir and ganciclovir have good effects on the treatment of EBV-IM, they have certain cytotoxicity, which can cause liver and kidney damage,
thrombocytopenia, gastrointestinal dysfunction, and other adverse reactions [19]. Therefore, clinicians are more cautious in their application to child patients. Studies have shown that intravenous infusion of ganciclovir and other drugs can achieve good curative effect, but it will also lead to an increase in adverse reactions [20]. In order to reduce the possible adverse reactions in children, all children in this study were treated with slow intravenous infusion (the infusion time was more than 1 hour). The treatment results showed that under the same dose and infusion method, the incidence rates of adverse reactions such as arrhythmia, liver dysfunction, and thrombocytopenia in the ganciclovir group were lower than those in the acyclovir group and the safety rate of ganciclovir was higher.

5. Conclusion

In the treatment of EBV-IM, the therapeutic effect of ganciclovir is obviously superior to that of acyclovir. Ganciclovir can quickly eliminate the symptoms of angina, fever, enlarged lymph nodes, and other signs in children, can improve abnormal blood indicators, and has a higher negative conversion rate of EBV and less adverse reactions.

Data Availability

The data used and/or analyzed during the current study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare no conflicts of interest.

Acknowledgments

This research was supported by the Traditional Chinese Medical Science and Technology Plan of Zhejiang Province (2020ZB188).

Table 2: Comparison of EBV-DNA negative conversion rate between two groups (n, %).

| Groups                  | Negative | Decline | No change |
|-------------------------|----------|---------|-----------|
| Acyclovir group (n = 64)| 39 (60.93) | 13      | 12        |
| Ganciclovir group (n = 64)| 52 (81.25) | 16      | 6         |
| χ² value               | 6.424    | 0.401   | 2.327     |
| P value                | 0.011    | 0.526   | 0.127     |

Table 3: Comparison of the incidence of adverse reactions between two groups (n, %).

| Groups                  | Arrhythmia | Abnormal liver function | Thrombocytopenia | Leukopenia | Gastrointestinal disorder | Total adverse reactions |
|-------------------------|------------|-------------------------|-----------------|------------|---------------------------|------------------------|
| Acyclovir group (n = 64)| 5          | 1                       | 2               | 3          | 4                         | 15 (23.44)             |
| Ganciclovir group (n = 64)| 0         | 0                       | 1               | 1          | 3                         | 5 (7.81)               |
| χ² value               |            |                         | 5.926           |            |                           |                        |
| P value                |            |                         | 0.015           |            |                           |                        |

References

[1] Y. Wu, S. Ma, L. Zhang et al., “Clinical manifestations and laboratory results of 61 children with infectious mononucleosis,” Journal of International Medical Research, vol. 48, no. 10, Article ID 300060520924550, 2020.
[2] A. Fugl and C. L. Andersen, “Epstein-barr virus and its association with disease-a review of relevance to general practice,” BMC Family Practice, vol. 20, no. 1, Article ID 62, 2019.
[3] J. Schwartzkopf, “Infectious mononucleosis,” Journal of the American Academy of Physician Assistants, vol. 31, no. 11, pp. 52-53, 2018.
[4] N. B. Wadé, C. M. Chang, C. M. Chang et al., “Infectious mononucleosis, immune genotypes, and non-Hodgkin lymphoma (NHL): an InterLymph Consortium study,” Cancer Causes & Control, vol. 31, no. 5, pp. 451–462, 2020.
[5] K. Klóski, A. Pietraszek, A. Karewicz, and M. Nowakowska, “Acyclovir in the treatment of herpes viruses-a review,” Current Medicinal Chemistry, vol. 27, no. 24, pp. 4118–4137, 2020.
[6] S. D. Krens, C. J. Hodiamont, N. P. Juffermans, R. A. A. Mathôt, and R. M. van Hest, “Population pharmacokinetics of ganciclovir in critically ill patients,” Therapeutic Drug Monitoring, vol. 42, no. 2, pp. 295–301, 2020.
[7] I. La Mantia, A. Varricchio, and C. Andaloro, “Pidotimod in children with infectious mononucleosis: a preliminary randomized controlled study,” Journal of Biological Regulators & Homeostatic Agents, vol. 34, no. 4, pp. 1597–1599, 2020.
[8] H. Van Noten, S. Markowicz, and S. Cappeliez, “Infectious mononucleosis resulting in acute necrotizing mediastinitis: a case report and literature review,” European Journal of Case Reports in Internal Medicine, vol. 7, no. 11, Article ID 1829, 2020.
[9] D. E. Greydanus and J. Merrick, “Infectious mononucleosis: be aware of its lethality!” International Journal of Adolescent Medicine and Health, vol. 31, no. 1, 2019.
[10] M. Xu, W. Zhou, X. Chen, Y. Zhou, B. He, and S. Tan, “Analysis of the biodegradation performance and biofouling in a halophilic MBBR-MBR to improve the treatment of disinfected saline wastewater,” Chemosphere, vol. 269, Article ID 128716, 2021.
[11] T. Ishii, Y. Sasaki, T. Maeda, F. Komatsu, T. Suzuki, and Y. Urita, “Clinical differentiation of infectious mononucleosis that is caused by epstein-barr virus or cytomegalovirus: a
single-center case-control study in Japan,” *Journal of Infection and Chemotherapy*, vol. 25, no. 6, pp. 431–436, 2019.

[12] A. Koşkun, S. Gökahmetoğlu, and P. Özmen, “Investigation of ganciclovir resistance in cytomegalovirus strains obtained from immunocompromised patients,” *Mikrobiyoloji Bulteni*, vol. 54, no. 4, pp. 619–628, 2020.

[13] M. Xu, H. Zhang, T. Tang et al., “Potential and applications of capillary electrophoresis for analyzing traditional Chinese medicine: a critical review,” *Analyst*, vol. 146, no. 15, pp. 4724–4736, 2021.

[14] A.-G. Märtson, D. Touw, K. Damman et al., “Ganciclovir therapeutic drug monitoring: a case series,” *Therapeutic Drug Monitoring*, vol. 41, no. 2, pp. 107–110, 2019.

[15] A. K. Schuster, B. C. Harder, F. C. Schlichtenbrede, M. N Jarczok, and J Tesarz, “Valacyclovir versus acyclovir for the treatment of herpes zoster ophthalmicus in immunocompetent patients,” *Cochrane Database of Systematic Reviews*, vol. 11, no. 11, Article ID D11503, 2016.

[16] D. F. Thompson and C. L. Ramos, “Antibiotic-induced rash in patients with infectious mononucleosis,” *The Annals of Pharmacotherapy*, vol. 51, no. 2, pp. 154–162, 2017.

[17] M. De Paor, K. O’Brien, and T. Fahey, “Antiviral agents for infectious mononucleosis (glandular fever),” *Cochrane Database of Systematic Reviews*, vol. 12, no. 12, Article ID D11487, 2016.

[18] K. Rostgaard, H. H. Balfour, R. Jarrett et al., “Primary Epstein-Barr virus infection with and without infectious mononucleosis,” *PLoS One*, vol. 14, no. 12, Article ID e226436, 2019.

[19] B. M. Ritchie, J. N. Barreto, E. F. Barreto et al., “Relationship of ganciclovir therapeutic drug monitoring with clinical efficacy and patient safety,” *Antimicrobial Agents and Chemotherapy*, vol. 63, no. 3, 2019.

[20] M. R. Reyes, C. L. Cabezas, E. C. Cidoncha, and D. S. Muner, “Dose banding of intravenous ganciclovir: banding scheme proposal and audit of toxicity and efficiency,” *Journal of Clinical Pharmacy and Therapeutics*, vol. 46, no. 3, pp. 767–771, 2021.